

VITAPCR IS AN INNOVATIVE RAPID MOLECULAR DIAGNOSTIC PLATFORM BASED ON REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) AMPLIFICATION TECHNOLOGY

VitaPCR allows the fast detection of infectious diseases in less than 20 minutes from sample to results. A real point-of-care solution.

VitaPCR has a compact and reliable design that does not require extra equipment. It is more accurate than conventional rapid testing.

VitaPCR SARS-CoV-2 Gen 2 Assay is used for the qualitative detection and discrimination of SARS-CoV-2 viral RNA in direct nasopharyngeal (NP) or oropharyngeal (OP) swabs from patients with signs and symptoms of COVID-19. The test allows the detection of SARS-CoV-2 in approximately 20 minutes.

VitaPCR Influenza/SARS-CoV-2 Assay is also available on the VitaPCR Instrument. This rapid RT-PCR test is used for the qualitative detection and discrimination of Influenza A, Influenza B and SARS-CoV-2 viral RNA in nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. Results are also available in 20 minutes.

Other swab specimen tests:

VitaPCR Influenza/RSV Assay (nasal or nasopharyngeal swab) VitaPCR Strep A Assay (oropharyngeal or throat swab)



2. LYSE

Stir the swab in the

collection buffer



3. TRANSFER

Use the

disposable pipette

Nº2



4. START Results delivered in less than 20 minutes



VITAPCR ADVANTAGES

EASY

COLLECT

NP or OP swabs

sample collection

Safe (virus inactivation) and simple 1-minute hands-on time preparation Minimal training required for operation (intuitive touchscreen guidance) Automated result interpretation

RAPID

From sample to result in 20 minutes The right diagnosis on the spot Improved patient management and triage



Can be deployed anywhere: 205 x 165 x 155 mm (L x W x H) - weight: 1,2 kg No additional equipment needed Room temperature storage (5 – 25 °C) and tests ready to use

SARS-COV-2 ASSAY

Limit of detection: 2,73 copies/µl of SARS-CoV-2 RNA (confidence ≥95%) No cross reactivity (Human Coronavirus 229E, Influenza A, Influenza B, Respiratory Syncytial Virus, Human Adenovirus type 1) Sensitivity: 99,3% - Specificity: 94,7% (*) Internal and external controls available



International Medical Products nv/sa 02 660 50 75 corona@intermed.be www.intermed.be